China's novel coronavirus pneumonia vaccine is developing in an orderly way, and experts hope to coo

The five routes of research and development of novel coronavirus vaccines that the Chinese government has supported are all advancing in an orderly manner. Experts hope to cooperate with international counterparts.

Wang GuiQiang, director of the Department of infectious diseases at Peking University First Hospital, said the Chinese government launched the vaccine research and development program as soon as possible. "Including adenovirus vector vaccine, inactivated vaccine, nucleic acid vaccine, etc. Among them, the adenovirus (vector) vaccine, like academician Chen Wei, first entered the clinical phase I, and now is carrying out the phase II clinical research. And the vaccines developed by China Bio and Kexing are also under clinical research. "

At the same time, Wang GuiQiang said that vaccine research and development is a big project. At present, China has carried out research and development cooperation with the United States, Germany, the United Kingdom and other countries.

Ms. Yan Jinghua, researcher of Institute of Microbiology, Chinese Academy of Sciences, said: "as a researcher of vaccine research and development, I especially hope to cooperate with international peers at present, because each laboratory and each enterprise has their own advantages. Putting these advantages together may speed up the research and development of vaccines and get safe and effective vaccines as soon as possible."

In addition, Liu Peipei, an expert from China Center for Disease Control and prevention, stressed at the meeting in response to the so-called "novel coronavirus artificial theory", that there is a basic consensus in the scientific community that the possibility of novel coronavirus artificial is very low, and this view was also expounded in the article published by many scientists in the academic journal The Lancet. The biggest possibility is that the virus is transmitted from natural host to intermediate host, and then from intermediate host to human.